Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form